A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT02863367
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Pancreatic Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib：500 mg，po，qd, d1-14, every 3 week
  • Gemcitabine — DRUG
    Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week

Study Details

Evaluate the efficacy and safety of Apatinib (500mg/d) with gemcitabine(1000mg/m2) in advanced metastatic pancreatic cancer.

Key Dates

Start date
Aug 31, 2016
Status verified
Jul 2016
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group
    Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: 1 years ]

Central Contacts

Related Studies